nCounter® PlexSet™ Reagents for Cell Line Screening

Helping Your Research

Accelerate your cell line screening and high-throughput applications with nCounter PlexSet Reagents for Gene Expression Analysis. PlexSet technology enables multiplexed gene expression assays to be performed more efficiently and cost effectively for projects ranging up to 96 RNA targets. Unlike other gene expression technologies, PlexSet reagents enable researchers to reduce their hands-on time by eliminating the need for cDNA conversion, replicate utilization, or RNA purification. Like other nCounter assays, Plexset reagents provides a simple and robust method for multiplexing targets without the need to optimize probes or amplification conditions.

Adherent cells, suspension cells, and primary cells

How It Works

The PlexSet reagents are based on proven nCounter technology utilizing molecular barcodes for highly multiplexed digital analysis.

01:

Multiplex up to 96 custom probes (or choose from preselected pathway panels) across 96 samples to generate 9,216 data points per run with only 30 minutes of hands-on time

02:

Utilization of lysed cells eliminates the need for RNA purification and amplification; save resources with an efficient workflow that does not require cDNA conversions, replicates, or prior probe optimizations

03:

Proven nCounter Digital Gene Expression technology provides excellent precision and reproducibility across a wide dynamic range

How it Works Video New multiplexed nCounter® PlexSet™ Reagents- an alternative to qPCR technology How it Works Video Challenges with GX Profiling and Recent Tech Advancements with NanoString PlexSet

How it Works Video Robust Digital Gx Profiling of up to 96 Targets in 96 Samples for Cell Line Screening

How it Works Video NanoString Scientists Reveal the “Secret Sauce” in Lysate Protocol Development

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Preselected Pathway Panels

Product Specifications

Preselected Pathway Panels

Looking for recommendations on panels in your application area? Check out the NanoString Panel Pro selection tool. Browse our catalog of preselected pathway panels by name, application area, biologic pathway/process, or gene name(s).

Expertly curated panels covering ~140 biological pathways and fields of interest for human, mouse, and rat samples.
Each panel contains 90 genes chosen to comprehensively cover each pathway involved in the topic.
All necessary controls and reference genes are included in each panel.
Customize by adding additional genes of interest to the panels (or omitting genes that are not of interest).

Product Specifications

Related Resources

See All Resouces

Product Bulletin PlexSet Reagents- Product Bulletin

Blog nCounter® PlexSet™ Reagents Let You Work Smarter, Not Harder

Multiplexing 96 Colorectal FFPE samples using Immuno-oncology PlexSet Preselected Panel

Efficient CRISPR Screening Using PlexSet

Infographic Compare PlexSet to PCR

Publications

View All Publications

Circadian rhythms in septic shock patients.

Background: Despite the intensive efforts to improve the diagnosis and therapy of sepsis over the last decade, the mortality of septic shock remains high and causes substantial socioeconomical burden of disease. The function of immune cells is time-of-day-dependent and is regulated by several circadian clock genes.

Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids.

BACKGROUND: Promoting full-length protein production is a requisite step to address some of the remaining unmet medical need for those with Cystic Fibrosis (CF) nonsense alleles. ELX-02 promotes read-through of mRNA transcripts bearing nonsense mutations, including the most common CF nonsense allele G542X, in several different preclinical models including human bronchial epithelial cells.

Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.

No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau.